
|Articles|August 19, 2019
ASRS 2019 Street Team: Raj K. Maturi, MD
Author(s)Julianne Mobilian
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
Advertisement
Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Timely interventions can protect vision in patients with GA
2
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
3
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
4
Monitoring MacTel: Why BCVA does not tell the whole story
5










































